Population
1020 consecutive patients who received glycoprotein IIb/IIIa inhibitors and underwent percutaneous coronary…
Design
Cohort
Authors
Loading...
May warrant heightened bleeding vigilance with GP IIb/IIIa inhibitors in older PCI patients with PVD; hypothesis-generating for tailored dosing.
In a real-world community hospital setting, the risk of bleeding with GP IIb/IIIa inhibitors during PCI is higher than in randomized trials, driven by factors such as older age, peripheral vascular disease, and higher aPTT levels.
Ali et al. (2004) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: